Direxion Daily Healthcare Bull 3X ETF (CURE)
CURE: Pullback In Healthcare Stocks Presents A Buying Opportunity
The Direxion Daily Healthcare Bull 3X ETF (CURE) has slipped in early 2026 as investors take profits after a strong performance in late 2025. The correction in healthcare stocks comes even as analysts envisage significant gains for CURE's ten largest holdings over the next 12 months. This dynamic may present an opportunity to rotate into CURE from the unlevereged XLV ETF, which tracks the same underlying index.
Which Sector Topped the Leaderboard for January Returns?
The first month of 2026 is already in the books. Which sector walked away with the top spot when it came to total returns?
CURE: The Leveraged ETF That Turbocharges The Leading U.S. Healthcare Stocks
Direxion Daily Healthcare Bull 3X Shares ETF has surged 83.5% since August 2025, reflecting bullish momentum in healthcare and pharma sectors. Reduced regulatory uncertainty, successful clinical trials, M&A activity, and prospects for 2026 rate cuts underpin the bullish thesis for CURE. CURE's leveraged structure amplifies both gains and losses, with significant time decay and risk, making it suitable only for tactical trading.
CURE: Analysts Strike A Cautious Tone Heading Into 2026
The Direxion Daily Healthcare Bull 3X Shares ETF has meaningfully outperformed the S&P 500 so far in 2025, benefiting from a recent shift in sentiment toward health care stocks. While CURE's underlying index is not as cheap as it was a few months ago, it still offers a roughly 19% forward P/E discount relative to the S&P 500. After strong recent returns, analysts project modest single-digit gains over the next 12 months for CURE's largest holdings.
Direxion's 5 Single-Stock ETFs, Including Coinbase and Robinhood
Direxion continues to expand its single-stock ETF offerings for tactical traders. It has introduced five new single stock funds that add exposure to Oracle, Coinbase, Robinhood, and Intel.
These Stocks Could Be Catalysts for CURE
The healthcare sector is catching some flack, and rightfully so. For the three years ending October 15, the S&P Health Care Select Sector Index returned just 22.9%.
Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset
Amid rising concerns about stagflation, investors have continued to bid up the equities sector. As evidence, the benchmark S&P 500 sector is up over 13% year-to-date.
Healthcare Sector Could Be on the Comeback Trail
Large-cap momentum names have been pushing the healthcare sector aside. Investors have primarily been flocking to Magnificent Seven names benefiting from the artificial intelligence (AI) push.
CURE: Adding Defensive Exposure Amid Frothy Market Valuations
The Direxion Daily Healthcare Bull 3X Shares ETF tracks an index composed of U.S. healthcare stocks. While the healthcare sector as a whole is essentially flat in 2025, the effect of beta slippage and a high expense ratio has resulted in CURE underperforming unleveraged ETFs. Looking ahead, CURE's underlying index trades at just 17.3x its forward earnings estimates, a wide discount relative to the S&P 500.
Top Performing Leveraged/Inverse ETFs: 08/17/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
CURE: Make an Adventurous Bet on an Undervalued Sector
The healthcare sector, the fifth-largest sector exposure in the S&P 500, was once a reliable destination for investors who wanted dependable performance without taking on significant risk. The group has lived up to its reputation for being less volatile than the broader market.
Top Performing Leveraged/Inverse ETFs: 07/27/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
CURE: A Useful Speculative Tool But Not An Investing Hold
CURE is designed for daily 3x leveraged exposure to the healthcare sector, making it suitable for short-term speculation or hedging, not long-term investment. Daily resets and derivatives costs cause value decay over time, so holding CURE for months or years leads to underperformance versus the underlying index. CURE is effective for tactical trades or hedges on short-term healthcare sector moves, but not for buy-and-hold strategies.
2 Sectors to Trade as Equity Funds See Higher Inflows
Sometimes traders can set up a potential plays when they see where investor money is flowing. This is available with fund inflows, which saw technology and healthcare equities gain a lion's share of February's flows.
5 Leveraged ETFs With Double-Digit Gains Halfway Through Q1
We highlight a bunch of the best-performing leveraged equity ETFs halfway through the first quarter.
Rising Number of Flu Cases Could Elevate These ETFs
Cases of the flu have reached elevated levels as of late. This could keep healthcare stocks and ETFs with a healthcare focus on the radar for traders.
5 Leveraged ETFs That Witnessed Double-Digit Gains in January
We highlight a bunch of the best-performing leveraged equity ETFs of January.
CURE: Analyst Estimates Point To Significant Gains In 2025
The Direxion Daily Healthcare Bull 3X Shares ETF seeks to deliver 300% (3x) of the return of an index focused on large-cap US healthcare stocks. Since October 2024 the forward P/E ratio for CURE's largest holdings has marginally increased. Even so Wall Street analysts predict a weighted average gain of 21% for CURE's top ten components over the next 12 months.
There Could Be Value in Healthcare Stocks Ahead of 2025
When a new presidential administration is set to take office, there's uncertainty as to whether specific sectors could be impacted. In the case of healthcare, that's certainly the case, especially in biotech.
CSE Bulletin: Consolidation - Biocure Technology Inc. (CURE.X)
Toronto, Ontario--(Newsfile Corp. - le 23 octobre/October 2024) - Biocure Technology Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every nine (9) pre-consolidated common shares. As a result, the outstanding shares of the company will be reduced to approximately 10,444,504 common shares.